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Abstract
Introduction: Interferon gamma (IFN-c) release assays, such as QuantiFERONH-TB Gold test (QFT-G) and QuantiFERONH-TB
Gold In-Tube test (QFT-GIT) are designed to detect M. tuberculosis (Mtb) infection. Recognition of unusual IFN-c
measurements may help indicate inaccurate results.
Methods: We examined QFT-G and QFT-GIT results from subjects who had two or more tests completed. We classified
unusual IFN-c measurements as: 1) High Nil Concentration (HNC) when IFN-c concentration in plasma from unstimulated
blood exceeded 0.7 IU/mL; 2) Low Mitogen Response (LMR) when Mitogen Response was ,0.5 IU/mL; 3) Very Low Mitogen
Response (VLMR) when Mitogen Response was #20.5 IU/mL; and 4) Very Low Antigen Response (VLAR) when the
response to a Mtb antigen was #20.35 IU/mL and #20.5 times the IFN-c concentration in plasma from unstimulated
blood.
Results: Among 5,309 results from 1,728 subjects, HNC occurred in 234 (4.4%) tests for 162 subjects, LMR in 108 (2.0%) tests
for 85 subjects, VLMR in 22 (0.4%) tests for 21 subjects, and VLAR in 41 (0.8%) tests for 39 subjects. QFT-GIT had fewer HNC,
VLMR, and VLAR (p=0.042, 0.004, and 0.067 respectively); QFT-G had fewer LMR (p=0.005). Twenty-four (51.6%) of 47
subjects with positive results and HNC were negative or indeterminate by all other tests. Thirteen (61.9%) of 21 subjects
with positive results and LMR were negative or indeterminate by all other tests.
Conclusion: Unusual IFN-c measurements including HNC, LMR, VLMR, and VLAR were encountered in small numbers, and
in most instances were not seen on simultaneously or subsequently performed tests. To avoid erroneous diagnosis of Mtb
infection, IGRAs with unusual IFN-c measurements should be repeated with another blood sample and interpreted with
caution if they recur.
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Introduction
Interferon gamma (IFN-c) release assays (IGRAs), such as the
QuantiFERON-TB Gold test (QFT-G) and QuantiFERON-TB
Gold In-Tube test (QFT-GIT) are being used as substitutes for the
tuberculin skin test (TST) to detect M. tuberculosis (Mtb) infection
with increasing frequency [1–3]. These whole blood IGRAs
depend on measurement of IFN-c released from sensitized
lymphocytes in whole blood incubated with specific Mtb antigens.
For QFT-G and QFT-GIT, aliquots of heparinized fresh whole
blood are incubated with Mtb antigens, with mitogen, and with no
antigen [4,5]. Plasma is harvested and the concentration of IFN-c
([IFN-c]) is determined by enzyme-linked immunosorbent assay
(ELISA). The amount of IFN-c released is determined by
subtracting the [IFN-c] in plasma from unstimulated blood
([Nil]) from the [IFN-c] in the plasma from blood stimulated
with Mtb antigen (‘‘Antigen Response’’), or mitogen (‘‘Mitogen
Response’’). QFT-GIT measures response to a single mixture of
peptides representing two whole Mtb proteins called early
secretory antigenic target 6 (ESAT-6) and culture filtrate protein
10 (CFP10), and part of a third Mtb protein called TB7.7 [6]. For
QFT-G, Mtb antigens consist of two separate mixtures of peptides
that represent either ESAT-6 or CFP10 that are used to stimulate
two separate aliquots of blood. Tests are considered positive when
the response to a Mtb antigen exceeds a predefined amount (e.g.
$0.35 IU/mL and $50% of [Nil]) although interpretation
criteria have changed for QFT-G [4,6,7] and QFT-GIT [5,8–
10] since their introduction. Mitogen-stimulated blood serves as a
positive control for both tests. A low Mitogen Response (i.e.
,0.5 IU/mL) may occur with insufficient lymphocytes, incorrect
addition of the Mitogen, labeling errors, reduced lymphocyte
activity due to prolonged specimen transport, improper specimen
handling, or the presence of antibodies to IFN-c [11]. The blood
incubated without antigen serves as a negative control. Elevated
levels of IFN-c in the negative control (i.e. .0.7 IU/mL) may
occur with incorrect addition of antigens, labeling errors, the
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tion. Currently, these IGRAs may be interpreted as positive
despite a low Mitogen Response or high [Nil] if the measured
response to a Mtb antigen exceeds the predefined cut point.
While these tests offer potential advantages over TST, technical
errors may affect their accuracy. Recognition of unusual IFN-c
measurements may help indicate inaccurate results. We developed
criteria for classifying IFN-c measurements as ‘‘unusual’’ based on
cut point values used to interpret QFT-G or QFT-GIT.
The objectives of this study were 1) to analyze a large
population of subjects who had multiple QFT-G and/or QFT-
GIT tests, 2) to determine the frequency of unusual IFN-c
measurements, 3) to determine how often unusual IFN-c
measurements occurred in multiple tests for a subject, and 4) to
determine which of the two test types had more unusual IFN-c
measurements.
Methods
Ethics Statement
The data included in this analysis were collected from multiple
studies conducted by the US Centers for Disease Control and
Prevention (CDC) from June 2003 to December 2008, including
three published reports [7,12,13]. Following CDC Human
Subjects Institutional Review Board approval, people being
screened for employment; people with symptoms, signs, or
radiographic evidence suggestive of tuberculosis; and people with
suspected exposure to Mtb were enrolled after providing written
informed consent. After providing an initial blood sample for
QFT-G and QFT-GIT, subjects were asked to return 2 to 12
weeks later to provide a second blood sample for repeat tests.
Results from subjects with at least two tests were included in this
analysis. The data were analyzed anonymously.
IGRAs
For QFT-G, test antigens consisted of two mixtures of
overlapping peptides representing the entire ESAT-6 protein or
CFP10 protein [7]. Antigens, saline (for nil control), or
phytohemagglutinin A (PHA; for mitogen control) were added
simultaneously to 1 mL aliquots of heparinized blood in CostarH
24-well microtiter plates. Plates were incubated within 12 hours of
collection for 16 to 24 hours at 37uC and plasma was harvested.
For QFT-GIT, 1 mL of blood was collected into 3 tubes
containing only heparin (nil control); heparin, dextrose, and PHA
(mitogen control); or heparin, dextrose, and Mtb antigens. Mtb
antigens for QFT-GIT consisted of a single mixture of peptides
representing ESAT-6, CFP10, and part of TB7.7 (Rv 2654, peptide
4) in one tube [14–16]. Blood was incubated within 12 hours of
collection for 16 to 24 hours at 37uC prior to harvesting plasma.
For QFT-G and QFT-GIT, the concentration of IFN-c in 50 ml
of each plasma sample was determined by ELISA as previously
described for the QuantiFERONH-TB Gold test [7]. Plasmas for
QFT-G and QFT-GIT from the same blood sample were assayed
at the same time and on the same ELISA plate. The Mitogen
Response was calculated by subtracting the IFN-c concentration
in plasma from unstimulated blood ([Nil]) from the IFN-c
concentration in plasma from mitogen-stimulated blood. For
QFT-G, antigen responses were calculated by subtracting [Nil]
from the IFN-c concentration in plasma from blood stimulated by
ESAT-6 (‘‘ESAT-6 Response’’) and CFP10 (‘‘CFP10 Response’’);
the higher of the ESAT-6 Response or CFP10 Response was used
as the TB Response to interpret QFT-G as described in Table 1.
For QFT-GIT, the antigen response was calculated by subtracting
[Nil] from the IFN-c concentration in plasma from blood
stimulated by the single cocktail of peptides representing ESAT-
6, CFP10, and part of TB7.7, and this was used as the TB
Response to interpret QFT-GIT as described in Table 1.
Classification of Unusual IFN-c Measurements
We classified unusual IFN-c measurements as: 1) High Nil
Concentration (HNC)w h e nI F N - c concentration in plasma from
unstimulated blood exceeded 0.7 IU/mL; 2) Low Mitogen Response
(LMR)w h e nM i t o g e nR e s p o n s ew a s,0.5 IU/mL; 3) Very low
Mitogen Response (VLMR) when Mitogen Response was #–0.5; and
4) Very Low Antigen Response (VLAR)w h e nar e s p o n s et oaMtb
antigenwas #–0.35 IU/mLand#–0.5 timesthe IFN-cconcentration
in plasma from unstimulated blood. These categories were not
mutually exclusive. The cut points were derived from cut point values
used to interpret QFT-G and/or QFT-GIT. The frequencies of the
unusual IFN-c measurements were then determined.
Statistical Analysis
Statistical analysis was conducted using SPSS (v15.0.1.1,
Chicago, Ill). Differences in the proportion of unusual IFN-c
measurements observed with QFT-G and QFT-GIT were assessed
using unadjusted Mantel-Haenszel oddsratios and the Pearson Chi-
Square test. P values #0.05 were considered significant.
Results
Test results were available for more than one test for 1,728
subjects. Of these, 181 were suspected to have tuberculosis, 683
Table 1. Interpretation Criteria used for QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube
a Tests.
Interpretation [Nil]
b TB Response
cd Mitogen Response
e
Positive Any $0.35 IU/mL and $50% of [Nil] Any
Negative #0.7 IU/mL ,0.35 IU/mL $0.5 IU/mL
Indeterminate #0.7 IU/mL ,0.35 IU/mL ,0.5 IU/mL
.0.7 IU/mL ,50% of Nil
c Any
aInterpretation criteria used for QFT-GIT differed from that approved by the FDA in Nov, 2008.
b‘‘[Nil]’’ is the IFN-c concentration in plasma from unstimulated blood.
c‘‘TB Response’’ for the QuantiFERON-TB Gold test is the higher IFN-c concentration in plasma from blood stimulated by a cocktail of peptides representing ESAT-6 or
CFP10, minus [Nil].
d‘‘TB Response’’ for the QuantiFERON-TB Gold In-Tube test is the IFN-c concentration in plasma from blood stimulated by a single cocktail of peptides representing
ESAT-6, CFP10, and part of TB7.7 minus [Nil].
e‘‘Mitogen Response’’ is the IFN-c concentration in plasma from mitogen stimulated blood minus [Nil].
doi:10.1371/journal.pone.0020061.t001
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were being screened for employment. Results from 4 tests (initial
QFT-G, repeat QFT-G, initial QFT-GIT, and repeat QFT-GIT)
were available for 841 subjects; results from 3 tests were available
for 171 subjects; and results from 2 tests were available for 716
subjects. Of the 5,309 test results examined, 711 (13.4%) results
were positive for Mtb infection; 4,338 (81.7%) results were
negative; and 260 (4.9%) were indeterminate. One or more tests
were positive for 325 (18.8%) subjects including 106 (58.6%)
subjects suspected to have TB, 198 (29.0%) subjects with suspected
exposure to tuberculosis, and 21 (2.4%) subjects being screened for
employment.
Frequency of Unusual IFN-c Measurements
Of the 5,309 results (Table 2), HNC occurred in 234 (4.4%)
tests for 162 subjects; LMR occurred in 108 (2.0%) tests for 85
subjects; VLMR occurred in 22 (0.4%) tests for 21 subjects, and
VLAR occurred in 41 (0.8%) tests for 39 subjects. Fifty-four tests
had more than one unusual IFN-c measurement. Fewer HNC and
VLMR were observed with QFT-GIT than QFT-G (p=0.042
and 0.005, respectively). Fewer VLAR were observed with QFT-
GIT than QFT-G, but this difference was not significant
(p=0.067). Conversely, significantly fewer LMR were observed
with QFT-G than QFT-GIT (p=0.004). As illustrated in Figure 1,
HNC occurred more than once in 55 (34.0%) of 162 subjects with
HNC; and LMR occurred more than once in 18 (21.2%) of 85
subjects with LMR; VLMR occurred multiple times in only 1
(4.8%) of 21 subjects with VLMR; VLAR occurred multiple times
in 2 (5.1%) of 39 subjects with VLAR. The number of subjects in
each subject group with 1 or more HNC, LMR, VLMR, and
VLAR differed significantly (Table 3).
Frequency of Unusual IFN-c Measurements Recurring
with the Same Test Format
Of 1,045 subjects who had initial and repeat QFT-G, 56
subjects had HNC on initial QFT-G and 14 (25.0%) of these had
a recurrent HNC (see Figure 2); 28 others had HNC only with
repeat QFT-G. Of 7 subjects who had LMR on initial QFT-G, 3
(42.9%) had a recurrent LMR; 12 others had LMR only with
repeat QFT-G. Five subjects had a VLMR on initial QFT-G and
only 1 (20.0%) had a recurrent VLMR. While 11 subjects had a
VLAR on initial QFT-G, none recurred (although 7 others had
VLAR on repeat QFT-G and not on initial QFT-G).
Of 915 subjects who had initial and repeat QFT-GIT, 32
subjects had HNC on initial QFT-GIT, 15 (46.9%) had HNC
recur, and 18 others had HNC occur only with repeat QFT-GIT
(see Figure 3). Of 23 subjects who had LMR on initial QFT-GIT,
8 (34.8%) had a recurrent LMR and 14 had LMR occur only with
repeat QFT-GIT. One person had a VLMR on the initial QFT-
GIT test without recurrence; 4 subjects had a VLAR on initial
QFT-GIT and none recurred.
Frequency of Unusual IFN-c Measurements with
Simultaneously Performed IGRAs
Among 1,617 subjects who had simultaneously performed
QFT-G and QFT-GIT, 56 subjects had HNC on QFT-G only, 40
had HNC on QFT-GIT only, and 40 (29.4%) of the 136 subjects
with HNC on QFT-G or QFT-GIT had HNC on both tests (see
Figure 4). LMR was observed in both QFT-G and QFT-GIT for
10 (13.5%) of 74 subjects with LMR on simultaneously performed
QFT-G or QFT-GIT. None of the subjects had VLMR with both
QFT-G and QFT-GIT when preformed simultaneously. VLAR
was observed in both QFT-G and QFT-GIT for 2 (5.7%) of 35
Table 2. Frequency of Unusual IFN-c Measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube Testing.
QFT-G
a QFT-GIT
b Total
c OR (95% CI)
d p value
# of tests 2741 2568 5309
# of subjects 1696 1653 1728
# (%) of tests with HNC
e 136 (5.0) 98 (3.8) 234 (4.4) 1.32 (1.01–1.72) 0.042
# (%) of subjects with HNC 122 83 162
# (%) of tests with LMR
f 41 (1.5) 67 (2.6) 108 (2.0) 0.57 (0. 38–0.84) 0.004
# (%) of subjects with LMR 38 59 85
# (%) of tests with VLMR
g 18 (0.7) 4 (0.2) 22 (0.4) 4.24 (1.42–12.54) 0.005
# (%) of subjects with VLMR 17 4 21
# (%) of tests with VLAR
h 27 (1.0) 14 (0.5) 41 (0.8) 1.82 (0.95–3.47) 0.067
# (%) of subjects with VLAR 27 14 39
# (%) of tests with any 1 or more Unusual IFN-c
Measurements
171 (6.2) 164 (6.4) 335 (6.3)
# (%) of subjects with any 1 or more Unusual IFN-
c Measurements
154 140 236
a‘‘QFT-G’’ is QuantiFERON-TB Gold test.
b‘‘QFT-GIT’’ is QuantiFERON-TB Gold In-Tube test.
c‘‘Total # of subjects’’ with unusual measurement may be less than the sum of the ‘‘# of subjects’’ with unusual QFT-G and QFT-GIT measurements because subjects
may have unusual measurements with both tests.
d‘‘OR (95% CI)’’ is odds ratio and 95% confidence interval for an unusual IFN-c measurement in QFT-G compared to referent, QFT-GIT.
e‘‘HNC’’ is High Nil Concentration (i.e. [Nil] over 0.7 IU/mL).
f‘‘LMR’’ is Low Mitogen Response (i.e. Mitogen Response under 0.5 IU/mL).
g‘‘VLMR’’ is Very Low Mitogen Response (i.e. Mitogen Response #20.5 IU/mL).
h‘‘VLAR’’ is Very Low Antigen Response (i.e. response to a Mtb antigen #20.35 IU/mL and #20.5 times [Nil]).
doi:10.1371/journal.pone.0020061.t002
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QFT-GIT.
Frequency of Positive Results with Unusual IFN-c
Measurements
HNC occurred in 58 positive tests for 47 subjects, 24 (51.6%) of
whom had negative or indeterminate results by all other IGRAs
examined. LMR occurred in 21 positive tests for 21 subjects, 13
(61.9%) of whom had negative or indeterminate results by all other
tests examined. One QFT-G with VLMR was interpreted as
positive (due to an ESAT-6 response of 17.9 IU/mL) while the TB
response measured by QFT-GIT performed at the same time was
0.01 IU/ml. No QFT-GIT with VLMR was interpreted as
positive. Three QFT-Gs with VLAR were interpreted as positive,
and in each case at least one other IGRA without unusual IFN-c
measurement was also interpreted as positive.
Discussion
We found unusual IFN-c measurements in 6.2% of QFT-G and
6.4% of QFT-GIT. Technical errors are a potential source for
many of the unusual IFN-c measurements we observed. Despite
the potential advantages of using whole blood IGRAs to detect
Mtb infection, these tests are more complex than the TST. While
TST requires five measurements to complete one test (i.e.
measurement of the volume of PPD to inject, the depth of
injection, the time injected, the time delay until measuring
induration, and measurement of induration size), QFT-G requires
at least 136 measurements to complete one test (listed as
supporting information in Table S1). The number of measure-
ments required to complete one QFT-GIT is reduced to 126
(listed as supporting information in Table S2) by combining test
antigens and including them in the tubes used to collect blood.
With so many measurements and associated manipulations, it is
easy to understand how technical errors could occur.
One scenario that could lead to VLMR for QFT-G or QFT-
GIT is transposition of nil and mitogen IFN-c measurements.
Additional evidence of this possibility comes from examination of
the Mitogen Response values. Of the 22 IGRAs with VLMR,1 1
(50%) had a Mitogen Response ,210 IU/mL (data not shown).
Similarly, VLAR could be due to transposition of measurements
for nil and TB antigens. By eliminating the need to add antigens
for QFT-GIT, the opportunity for transpositions is reduced, and
Table 3. Subjects in Each Group with Unusual IFN-c
Measurements.
Group
$1
HNC
a
$1
LMR
b
$1
VLMR
c $1 VLAR
d
Total n (%) n (%) n (%) n (%)
Employee Screening 864 35 (4.1) 12 (1.4) 0 (0) 12 (1.4)
Contacts 683 103 (15.1) 50 (7.3) 11 (1.6) 23 (3.4)
TB Suspect 181 24(13.3) 23 (12.7) 10 (5.5) 4 (2.2)
p value ,0.001 ,0.001 ,0.001 0.03
a‘‘HNC’’ is High Nil Concentration (i.e. [Nil] over 0.7 IU/mL).
b‘‘LMR’’ is Low Mitogen Response (i.e. Mitogen Response under 0.5 IU/mL).
c‘‘VLMR’’ is Very Low Mitogen Response (i.e. Mitogen Response #20.5 IU/mL).
d‘‘VLAR’’ is Very Low Antigen Response (i.e. response to a Mtb antigen
#20.35 IU/mL and #20.5 IU/mL).
doi:10.1371/journal.pone.0020061.t003
Figure 2. Number of subjects with unusual IFN-c measure-
ments when QuantiFERON-TB Gold tests were repeated. The
number of subjects with unusual IFN-c measurements categorized as
High Nil Concentration (HNC), Low Mitogen Response (LMR), Very Low
Mitogen Response (VLMR), and Very Low Antigen Response (VLAR)
that occurred only with the initial test (light gray bars), with the repeat
test (dark gray bars), or in both the initial and repeat test (medium gray
bars) among 1,044 Subjects with Initial and Repeat QuantiFERON-TB
Gold Test Results.
doi:10.1371/journal.pone.0020061.g002
Figure 1. Number of subjects with unusual IFN-c measure-
ments. The number of subjects with unusual IFN-c measurements
categorized as High Nil Concentration (HNC), Low Mitogen Response
(LMR), Very Low Mitogen Response (VLMR), and Very Low Antigen
Response (VLAR) that occurred once (dark gray bars) or more than
once (light gray bars) among 1,725 subjects who had 5,309
QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube Tests
performed.
doi:10.1371/journal.pone.0020061.g001
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for QFT-GIT as compared to QFT-G. Additional evidence that
some VLMR and VLAR are the result of technical errors is the
rarity of their recurrence with subsequent testing. VLMR recurred
in only one person and VLAR did not recur. Also, for most
subjects with VLMR or VLAR, such unusual IFN-c measure-
ments were not seen on a simultaneously performed IGRA.
While LMR has been associated with immune suppression
[10,17], technical errors may produce indistinguishable results. If
due to immune suppression, LMR would be expected on
simultaneously performed tests, but only 13.5% of subjects who
had LMR and a simultaneously performed IGRA had it on a the
simultaneously performed IGRA. Additionally, LMR occurred in
more than one test for only 21.2% of the subjects who had LMR.
The same transpositions that cause LMR and VLMR could
account for a portion of the unusual IFN-c measurements
classified as HNC. However, in most situations, HNC occurred
where transpositions were not suspected (i.e. without LMR,
VLMR or VLAR). Other technical factors may be involved as is
suggested by our observations that HNC occurred less often with
QFT-GIT as compared to QFT-G, that HNC was rarely seen on
two simultaneously performed IGRAs for the same person, and
that HNC recurrence was uncommon. These findings suggest that
tests with such unusual IFN-c measurements should be repeated.
Sensitization to mouse antigens can generate heterophile
antibodies in some people. These antibodies can bind to the
capture and detection antibodies used in IGRAs and generate
results consistent with HNC. Elevated levels of IFN-c are seen in
various infectious diseases (e.g., tuberculosis, acquired immuno-
deficiency syndrome, parasite diseases), autoimmune diseases (e.g.,
rheumatoid arthritis, thyroiditis, systemic lupus), and in allograft
rejection. HNC would be expected to occur more frequently in
patients with these conditions. Day-to-day variation in disease
activity or changes in the amount of heterophile antibody present
may explain some difference in HNC observed with initial and
repeat testing. However, day-to-day variation would not explain
difference in HNC observed when two IGRAs are performed
simultaneously.
Technical errors appear to contribute to IGRA variability.
However, data related to IGRA variability are scarce [18,19]. This
is in part because of the complexity of these tests. For example,
reproducible QFT-GIT results require accurate measurement of
[IFN-c] in 3 samples in the correct order, and the use of multiple
criteria for test interpretation. While testing samples by ELISA are
traditionally performed in duplicate or triplicate, the manufacturer
of QFT-G and QFT-GIT recommends testing once. Our review
of results of multiple tests from the same person performed
simultaneously and serially provided an opportunity to recognize
unusual IFN-c measurements, most of which were aberrant and
seen only in one of multiple tests examined. The observation that
most unusual IFN-c are aberrant supports the recommendation to
repeat testing using a fresh sample when unusual IFN-c are
encountered [2]. Additional studies comparing IGRA results
performed multiple times on the same sample, performed on
multiple samples collected at the same time, and performed on
multiple samples collected at different times are needed to more
fully assess IGRA reproducibility. Recognition of unusual IFN-c
measurements and the potential for technical errors will facilitate
assessment of IGRA reproducibility.
Figure 3. Number of subjects with unusual IFN-c measure-
ments when QuantiFERON-TB Gold In-Tube tests were repeat-
ed. The number of subjects with unusual IFN-c measurements
categorized as High Nil Concentration (HNC), Low Mitogen Response
(LMR), Very Low Mitogen Response (VLMR), and Very Low Antigen
Response (VLAR) that occurred only with the initial test (light gray
bars), with the repeat test (dark gray bars), or in both the initial and
repeat test (medium gray bars) among 915 subjects with initial and
repeat QuantiFERON-TB Gold In-Tube test results.
doi:10.1371/journal.pone.0020061.g003
Figure 4. Number of subjects with unusual IFN-c measure-
ments when QuantiFERON-TB Gold and QuantiFERON-TB Gold
In-Tube tests were run simultaneously. The number of subjects
with unusual IFN-c measurements categorized as High Nil Concentra-
tion (HNC), Low Mitogen Response (LMR), Very Low Mitogen Response
(VLMR), and Very Low Antigen Response (VLAR) that occurred only
with the QuantiFERON-TB Gold test (light gray bars), with the
QuantiFERON-TB Gold In-Tube test (dark gray bars), or in both the
QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube test (medium
gray bars) among 1,617 subjects with simultaneously performed
QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube Test.
doi:10.1371/journal.pone.0020061.g004
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despite unusual IFN-c measurements. In our study 21.4% of
positive results were associated with unusual IFN-c measurements.
The observation that 51.1% of subjects with positive results
associated with HNC and 61.9% of positive results associated with
LMR had negative or indeterminate results by all other tests
examined raises doubt as to their validity. It would seem that tests
with unusual IFN-c measurements should be interpreted as
indeterminate regardless of the measured response to TB antigens.
Criteria for interpreting tests with high [Nil] have evolved.
Initial criteria did not include an indeterminate category for tests
with HNC [6,9]. With FDA approval of QFT-G, indeterminate
criteria were included for most tests with [Nil] over 0.7 IU/mL
[4]. With FDA approval of QFT-GIT, indeterminate criteria were
included for tests with [Nil] over 8.0 IU/mL [5]. Our observations
suggest that raising the cutoff for identifying high [Nil] may result
in an increased number of inaccurate interpretations.
While HNC, VLMR, and VLAR were more common with
QFT-G than QFT-GIT, LMR was more common with QFT-
GIT. One difference that may account for these observations is
how blood is mixed with antigens. Including the antigens in the
blood collection tubes reduces the complexity of QFT-GIT and
reduces the opportunity for technical errors, but necessitates
shaking the blood vigorously to dissolve the antigens and mix them
with the blood. LMR may follow inadequate shaking due to
incomplete integration of the mitogen with the blood, and
excessive shaking may result in lysis of lymphocytes and reduced
production of IFN-c. Similar problems with tubes containing Mtb
antigens could occur, but would be difficult to detect.
A limitation of this study is our inability to confirm the presence
or absence of Mtb infection. We addressed this lack of an adequate
diagnostic standard by comparing results of multiple tests from the
same person performed simultaneously and serially.
In conclusion, unusual IFN-c measurements such as HNC,
LMR, VLMR, and VLAR were encountered in a small number
of QFT-G and QFT-GIT, and in most cases, such measurements
were not seen on simultaneously or subsequently performed tests.
To avoid erroneous diagnosis of Mtb infection, QFT-G and QFT-
GIT with unusual IFN-c measurements should be repeated with
another blood sample and interpreted with caution if they recur.
Supporting Information
Table S1 Measurements required for one Quanti-
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